LSI

AI technology faces a higher bar for adoption, so how can companies get doctors and admin on board? Vektor Medical, Inc. Medical has found success by allowing doctors to use their system 10 to 20 times, helping them become comfortable and see the benefits firsthand. As a result, these doctors have become major advocates, making the case to their administrators about the system's positive impact on patient care and its necessity in their practice. Want to learn more about how companies are driving adoption of AI in healthcare? Tune into the full panel, “Advent of AI: What Will it Take to Drive True Adoption in Clinical Workflows?” where our panelists discuss the real-world challenges and successes of AI adoption in healthcare, from data quality and regulatory hurdles to the importance of clinical trials and the human element in AI integration. Featured Panelists:  • Natasha Allen (Moderator), Partner, Foley & Lardner LLP • Robert J. Krummen, CEO, Vektor Medical, Inc. • Daniel Hawkins, CEO, Vista.ai • Sascha Berger, Healthcare Investor The full panel, “Advent of AI: What Will it Take to Drive True Adoption in Clinical Workflows?” is available on our website and YouTube channel.

LN Robotics (#LSIAlumni) raised a ₩20 billion ($14.5 million) Series B funding round led by LB Investment, a leading venture capital firm in Korea. Industrial Bank of Korea and KB Investment joined as new investors, with follow-on investments from Mirae Asset Venture Investment and Stick Ventures. The company will use the funding to enter the domestic and overseas markets for its cardiovascular interventional robot. LN Robotics’ flagship product is the AVIAR system, Korea's first cardiovascular intervention assist robot system. The initial focus of the AVIAR system is PCI (Percutaneous Coronary Intervention) to treat cardiovascular diseases, which are on of the top causes of death worldwide. Congratulations to LSI Alumni, Jan Östman, Head of US operations, Jaesoon Choi, CEO & CTO, and the entire LN Robotics team on this incredible milestone. To learn more about LN Robotics, watch Jan Östman’s full video presentation from LSI USA ‘24. Available on our website and YouTube channel.

Last week, I spoke to our company about the “moments” that have defined LSI. Today, I’m thrilled to share the next one — Henry Peck has taken on the role of Chief Business Officer at LSI, as we continue the global expansion of our events, market intelligence, media and *more (see footnote). From the day I met Henry at LSI USA ‘21 as an innovator raising capital, I knew he was someone I wanted on our team. Fast-forward, and through his first two years at LSI, his impact has been enormous — From architecting our insights and content programs, to spearheading our brand evolution, working hand-in-hand with leaders in the innovation and investment ecosystem to raise the bar for our events, and building the internal and external infrastructure for LSI’s expansion into new markets and geographies, Henry and his team’s fingerprints can be seen on all areas of our business. Of the “moments” I and LSI have lived to tell the tale of, from surviving the 2008 financial crisis so close to our inception to re-opening our doors in the wake of COVID in 2021, this is perhaps our most significant yet… We’re bringing our industry-leading Emerging Medtech Summit to APAC, the fastest growing region in Medtech (per our in-house analysts). We’re investing in our research, data, and product capabilities to support event more healthcare enterprises in making smarter decisions. We’re launching new offerings to better serve our global community of innovators, investors, strategics, professional service providers and more. I’m proud of the moments we’ve experienced over the past two decades, and am more excited than ever about the next two, with Henry’s new role playing a crucial part in that. Please join me in congratulating Henry, our new CBO. *This is just the beginning of more exciting work we'll be sharing about in the coming months, so stay tuned. Henry and I, along with our team, can't wait to share more behind-the-scenes work we've been doing. All aimed at supporting and adding even more value to this industry and community we are committed to.

Want to leave LSI Europe ‘24 with your own original content telling your company story? You can tell your story in our world-class production studio at the event this September. When you tell your story in our studio, you get more than just a recording - you get a comprehensive, professionally-curated media package, ready to be used in everything from your marketing channels to investor materials and more. Content from LSI's studio is also distributed on our website and social media channels, and available to our market intelligence platform subscribers, further amplifying your message to a global network of investors, strategics, innovators, and more. There is still limited availability left in our studio. If you’re interested in booking space in the LSI Studio, get in touch with us today. PS: The studio interviews will be held at the beautiful Penha Longa Resort monastery, providing a unique and stunning backdrop, as pictured below.

With less than 50 days to go we’re giving you a first look at the global investors confirmed to join us at LSI Europe ‘24 this September in Sintra, Portugal. Here’s a sneak peek of 25: • Gilad Glick, Vice President, Venture Investments — Medtech, JJDC • Murielle Thinard McLane, Managing Partner & President, Intuitive Ventures • Antoine Papiernik, Chairman & Managing Partner, Sofinnova Partners • Ittai Harel, Managing General Partner, Pitango Venture Capital • Marta G. Zanchi, Founder & Managing Partner, Nina Capital • Carissa Bellardine Black, Senior Director, Venture Capital, Medtronic • Josh Makower, Venture Partner, Sofinnova Partners • Diana Saraceni, Co-Founder & General Partner, Panakes Partners • Colin Morrison, Senior Director of Venture Capital, Boston Scientific • Nate Harrington, Managing Partner, Philips Ventures • Celia Hart, General Partner, Supernova Invest • Soyoung Park, Venture Partner, VU Venture Partners • Samuel Levy, Founding Partner, Lauxera Capital Partners • Sascha Berger, Healthcare Investor • Susana Amorim Lopes, Venture Investor, Gilde Healthcare • Nick Pachuda, Innovation & New Ventures, Precision Life Science Partners • Nathalie Van Bruaene, Investment Manager Life Science & Care, PMV • Bob Crutchfield, Partner, Good Growth Capital • Thom Rasche, Managing Partner, Earlybird Venture Capital • Roberta Ferrari, Managing Partner, EQT Life Sciences • Nir G., Technology Development Manager, Mayo Clinic Ventures • Tyler Wanke, Investor, Wanke Family Office • Fernando Pacheco, Investment Director, Endeavour Vision • Auriel August, MD, Principal, Santé Ventures • Dr. Gal Noyman - Veksler, Partner, LionBird • Sascha Alilovic, Managing Partner, SHS Capital • Anke Cassing, Principal, High-Tech Grunderfonds This is just the beginning. If you're looking to connect with industry-leading investors (venture capital, private equity, angel groups, accelerators, etc.), this is the place to do it. View more confirmed investors on our website. Interested in speaking, presenting, or exhibiting at LSI Europe '24? Join nearly 1,000 global Medtech and Healthtech leaders in Sintra, Portugal this September 16-20th. Apply today while space is still available.

Hot off the press! The latest edition of The Memo, featuring Andrew Cameron, Founder & CEO of FeelTect is out now. 🗞 Here’s a preview of this week’s edition of our weekly newsletter, The Memo: The Irish startup, led by Founder & CEO Andrew Cameron, is pioneering a new era in compression therapy for venous leg ulcers, aiming to improve patient outcomes and alleviate the burden on healthcare systems. The Current Landscape Venous leg ulcers continue to be a growing problem, particularly in aging populations and among individuals with comorbidities such as obesity. "In the last five years, the number of venous leg ulcers in the UK has doubled, and the healing rate has decreased by 20%," Cameron points out. This surge in cases is straining healthcare systems already burdened by limited resources and a shortage of trained nurses. Compression therapy has long been the standard of care for venous leg ulcers, a condition resulting from the breakdown of valves in the leg veins. This therapy, which dates back over 500 years, helps restore blood flow and heal wounds. However, its application remains fraught with challenges. "Compression is applied totally blind. There's a 90% failure rate to achieve targeted pressure in clinical practice. Too tight is dangerous, too loose is ineffective," Cameron explains. Nurses and caregivers often apply compression with little or no guidance leading to a lack of pressure measurement during application. "Only about 2% of patients are seen by trained tissue viability nurses," says Cameron. "Even if the pressure is applied correctly, it can lose up to 50% of its effectiveness within the first three days due to the reduction in swelling." This variability can lead to prolonged healing times and frequent recurrence of ulcers. Continue Reading: https://lnkd.in/grM6bnGg

Wait a second — is that a new batch of milestones from the hottest companies in Medtech? This week the #LSIAlumni raised over $100 million, received FDA clearances, added new members to their leadership teams, and much more on the road to #LSIEurope24 Your 60-second news recap: 4D Biomaterials — Phil Smith → Parent company, 4D Medicine Ltd, raised a £3.4m investment deal led by Oshen Holdings with participation from DSW Ventures, SFC Capital, Boundary Capital Partners LLP, and a number of private angel investors Activ Surgical — Manisha Shah-Bugaj → Announced a partnership with Medbionix, a leading medical technology distributor in Southern India Aspero Medical — Mark Rentschler, Trae Gordon → Announced that Eddie Gobran, Managing Partner of Leva Capital, has joined the Board of Directors Bone Health Technologies — Laura Yecies → Announced the company has acquired Wellen, a Brooklyn-based health technology company reinventing exercise-based osteoporosis care as a personalized and science-backed solution Brainomix — Michalis Papadakis → Announced new study data validating its AI technology across US stroke networks eCential Robotics → Received FDA 510(k) clearance, announced the Appointment of Clement Vidal as new CEO, and successfully completed the first spine surgery using eCential Robotics’ Open Spine Robot, with Spineart Compatible Implants FibriCheck — Lars Grieten, Bieke Van Gorp → Received FDA clearance for the entire FibriCheck ecosystem Flosonics Medical — Joe Eibl → Announced that Sutter Health is set to implement Flosonics' wireless, wearable Doppler ultrasound device, FloPatch, to enhance the safety of intensive care unit (ICU) patients ICHOR Vascular Inc. — Tim Blair → Received FDA 510(k) clearance for its 7-F peripheral reperfusion system Inspire Medical Systems — William Inglis → Received CE Mark certification of full-body MRI compatibility for its Inspire IV neurostimulator device IRegained Inc. — Vineet Johnson → Announced the commercial launch of the MyHand System, a post-stroke medical device system designed to aid hand function disability Magenta Medical Ltd. — David Israeli, MD → Closed a $105 million financing round led by Novo Holdings. New investors Viking Global Investors and RA Capital Management, and existing investors OrbiMed, New Enterprise Associates (NEA), JVC Investment Partners, and ALIVE - Israel HealthTech Fund, also participated in the round sentiar — Berk Tas → Announced the successful completion of the first holographic cardiac ablation guided by SentiAR's CommandEP system THINK Surgical — Stuart Simpson → Received FDA 510(k) clearance for its TMINI® Miniature Robotic System (TMINI 1.1) Valcare Medical — Steve Sandweg → Announced the expansion of the AMEND™ TS EU Pilot Study to Italy Volta Medical — Théophile Mohr Durdez → Entered into Joint Development Agreement with GE HealthCare to enhance arrhythmia procedures Congratulations to all the LSI Alumni who made major news this week!

Traditional ECG interpretation approaches are inadequate due to their frequent inaccuracies, lengthy result turnaround times, and lack of accessibility, particularly in remote or resource-limited settings. AccurKardia is addressing these issues with its flagship product, the AccurECG™ Analysis System. It’s an FDA-cleared, cloud-based, device-agnostic, and fully automated electrocardiogram (ECG) interpretation software platform. The software provides an array of benefits, such as beat-by-beat analysis, ventricular/supraventricular ectopic beat detection, heart rate measurement, and automated interpretation of 13 different heart rhythms including sinus tachycardia, sinus bradycardia, atrial fibrillation, and atrial flutter, among others. The fully automated output of AccurECG™ improves clinicians’ review efficiencies and enables prompt treatment of patients, with results delivered in minutes instead of days or weeks. It is indicated for adults aged 22 and older. Catch the latest from AccurKardia. Tune into Juan C Jimenez and Moin Hussaini’s Studio Interview and presentation from LSI USA ‘24 to learn more about AccurKardia’s recent progress. Available now on our website and YouTube channel.

In anticipation of LSI Asia ‘25, we’re showcasing the incredible innovation from the #LSIAlumni in Asia. It’s the innovators like these that get us excited to bring LSI Asia to Singapore in June 2025. Today, we’re showcasing Vyasaraj Manakari, Co-Founder & CEO of Magloy Tech. The company is pioneering the future of medical implants with its innovative bioresorbable magnesium technology. Magloy Tech’s flagship product, ResoMag®, is an advanced bioresorbable magnesium technology offering unparalleled mechanical stability and controlled degradation thereby fostering efficient bone healing. Designed to dissolve naturally, their implants, including state-of-the-art cranial plating systems and compression screws, leave healthy bone tissue, significantly lowering the risks associated with traditional implants. To learn more about Magloy Tech, watch Vyasaraj’s full video presentation from LSI USA ‘24. Available on our website and YouTube channel. Want to join us at LSI Asia ‘25? Registration, applications for presenters, sponsorship opportunities, and our special hotel block rates are now open. Secure your spot today to join us at LSI Asia ‘25 on June 10th-13th at The Ritz-Carlton, Millenia Singapore.

AI is poised to revolutionize healthcare, but what will it take to integrate it into clinical workflows? Our recent panel at LSI USA '24 tackled this question head-on. Our expert panelists discuss the real-world challenges and successes of AI adoption in healthcare, from data quality and regulatory hurdles to the importance of clinical trials and the human element in AI integration. Tune into the full panel to hear advice and nuanced perspectives from: • Natasha Allen (Moderator), Partner, Foley & Lardner LLP • Sascha Berger, Healthcare Investor • Robert J. Krummen, CEO, Vektor Medical, Inc. • Daniel Hawkins, CEO, Vista.ai The full panel, “Advent of AI: What Will it Take to Drive True Adoption in Clinical Workflows?” is available on our website and YouTube channel.